Loading stock data…
GeneDx Holdings Corp. (WGS)
$85.87-0.12 (-0.14%)
Market ClosedLast close Sep 8
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeneDx Holdings Corp. in the Healthcare sector is trading at $85.87 with a market capitalization of $2.6B. Wall Street consensus targets $90.44 (9 analysts), implying a +5.3% move over the next 12 months. The stock is currently 50% below its 52-week high of $170.87, remaining 1.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $102.25M↓ | $120.99M↑ | $116.74M↑ | $102.69M↑ | $87.11M |
| Gross Profit | $68.21M↓ | $84.27M↓ | $84.53M↑ | $70.90M↑ | $58.48M |
| Operating Income | -$26.18M↓ | -$14.23M↓ | -$3.25M↓ | $8.96M↑ | -$4.55M |
| Net Income | -$63.32M↓ | -$17.67M↓ | -$7.63M↓ | $10.81M↑ | -$6.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.55%
Volume
Today's trading volume
426,356
Recent News
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Top Stock Picks for Week of August 24, 2026
A Semiconductor Packaging Company with Strong Financial Momentum and a Medical Services Company with Solid Short-Term Price Momentum.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GeneDx (WGS) Q2 2026 Earnings Call Transcript
Genomic testing volume surged 32% as profitability returned ahead of schedule.
GeneDx Holdings (WGS) Is Up 18.4% After Reaffirming 2026 Outlook And Raising Equity From Blackstone
In early August 2026, GeneDx Holdings Corp. reported second-quarter revenue of US$114.44 million with a net loss of US$17.74 million, reaffirmed its full-year 2026 revenue outlook, and announced a private placement of 81,967 Class A shares at US$61.00 each with participation from a Blackstone affiliate. The combination of higher revenue alongside a shift from profit to loss, together with fresh equity capital from a major institutional investor, gives investors new information on GeneDx’s...